Literature DB >> 31611383

Quantitative structural assessment of graded receptor agonism.

Jinsai Shang1, Richard Brust1, Patrick R Griffin1,2, Theodore M Kamenecka2, Douglas J Kojetin3,2.   

Abstract

Ligand-receptor interactions, which are ubiquitous in physiology, are described by theoretical models of receptor pharmacology. Structural evidence for graded efficacy receptor conformations predicted by receptor theory has been limited but is critical to fully validate theoretical models. We applied quantitative structure-function approaches to characterize the effects of structurally similar and structurally diverse agonists on the conformational ensemble of nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ). For all ligands, agonist functional efficacy is correlated to a shift in the conformational ensemble equilibrium from a ground state toward an active state, which is detected by NMR spectroscopy but not observed in crystal structures. For the structurally similar ligands, ligand potency and affinity are also correlated to efficacy and conformation, indicating ligand residence times among related analogs may influence receptor conformation and function. Our results derived from quantitative graded activity-conformation correlations provide experimental evidence and a platform with which to extend and test theoretical models of receptor pharmacology to more accurately describe and predict ligand-dependent receptor activity.

Entities:  

Keywords:  NMR spectroscopy; X-ray crystallography; ligand binding; nuclear receptor; receptor theory

Year:  2019        PMID: 31611383      PMCID: PMC6825269          DOI: 10.1073/pnas.1909016116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  61 in total

Review 1.  Tactical Approaches to Interconverting GPCR Agonists and Antagonists.

Authors:  Peter I Dosa; Elizabeth Ambrose Amin
Journal:  J Med Chem       Date:  2015-09-21       Impact factor: 7.446

2.  Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.

Authors:  Richard Brust; Hua Lin; Jakob Fuhrmann; Alice Asteian; Theodore M Kamenecka; Douglas J Kojetin
Journal:  ACS Chem Biol       Date:  2017-02-16       Impact factor: 5.100

3.  Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis.

Authors:  Kai Ge; Mohamed Guermah; Chao-Xing Yuan; Mitsuhiro Ito; Annika E Wallberg; Bruce M Spiegelman; Robert G Roeder
Journal:  Nature       Date:  2002-05-30       Impact factor: 49.962

4.  Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor.

Authors:  Matthew T Eddy; Ming-Yue Lee; Zhan-Guo Gao; Kate L White; Tatiana Didenko; Reto Horst; Martin Audet; Pawel Stanczak; Kyle M McClary; Gye Won Han; Kenneth A Jacobson; Raymond C Stevens; Kurt Wüthrich
Journal:  Cell       Date:  2017-12-28       Impact factor: 41.582

5.  A2A adenosine receptor functional states characterized by 19F-NMR.

Authors:  Lukas Sušac; Matthew T Eddy; Tatiana Didenko; Raymond C Stevens; Kurt Wüthrich
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-21       Impact factor: 11.205

6.  The dynamic process of β(2)-adrenergic receptor activation.

Authors:  Rie Nygaard; Yaozhong Zou; Ron O Dror; Thomas J Mildorf; Daniel H Arlow; Aashish Manglik; Albert C Pan; Corey W Liu; Juan José Fung; Michael P Bokoch; Foon Sun Thian; Tong Sun Kobilka; David E Shaw; Luciano Mueller; R Scott Prosser; Brian K Kobilka
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

Review 7.  The role of dynamic conformational ensembles in biomolecular recognition.

Authors:  David D Boehr; Ruth Nussinov; Peter E Wright
Journal:  Nat Chem Biol       Date:  2009-11       Impact factor: 15.040

8.  Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists.

Authors:  Marcelo Vizoná Liberato; Alessandro S Nascimento; Steven D Ayers; Jean Z Lin; Aleksandra Cvoro; Rodrigo L Silveira; Leandro Martínez; Paulo C T Souza; Daniel Saidemberg; Tuo Deng; Angela Angelica Amato; Marie Togashi; Willa A Hsueh; Kevin Phillips; Mário Sérgio Palma; Francisco A R Neves; Munir S Skaf; Paul Webb; Igor Polikarpov
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

9.  Pharmacological repression of PPARγ promotes osteogenesis.

Authors:  David P Marciano; Dana S Kuruvilla; Siddaraju V Boregowda; Alice Asteian; Travis S Hughes; Ruben Garcia-Ordonez; Cesar A Corzo; Tanya M Khan; Scott J Novick; HaJeung Park; Douglas J Kojetin; Donald G Phinney; John B Bruning; Theodore M Kamenecka; Patrick R Griffin
Journal:  Nat Commun       Date:  2015-06-12       Impact factor: 14.919

10.  An alternate binding site for PPARγ ligands.

Authors:  Travis S Hughes; Pankaj Kumar Giri; Ian Mitchelle S de Vera; David P Marciano; Dana S Kuruvilla; Youseung Shin; Anne-Laure Blayo; Theodore M Kamenecka; Thomas P Burris; Patrick R Griffin; Douglas J Kojetin
Journal:  Nat Commun       Date:  2014-04-07       Impact factor: 14.919

View more
  4 in total

1.  Delineation of the molecular determinants of the unique allosteric binding site of the orphan nuclear receptor RORγt.

Authors:  Iris A Leijten-van de Gevel; Luc Brunsveld
Journal:  J Biol Chem       Date:  2020-05-20       Impact factor: 5.157

2.  Structural mechanism underlying ligand binding and activation of PPARγ.

Authors:  Jinsai Shang; Douglas J Kojetin
Journal:  Structure       Date:  2021-03-12       Impact factor: 5.871

3.  Cooperativity as quantification and optimization paradigm for nuclear receptor modulators.

Authors:  Pim J de Vink; Auke A Koops; Giulia D'Arrigo; Gabriele Cruciani; Francesca Spyrakis; Luc Brunsveld
Journal:  Chem Sci       Date:  2022-01-19       Impact factor: 9.825

4.  Ligand-induced shifts in conformational ensembles that describe transcriptional activation.

Authors:  Sabab Hasan Khan; Sean M Braet; Stephen John Koehler; Elizabeth Elacqua; Ganesh Srinivasan Anand; C Denise Okafor
Journal:  Elife       Date:  2022-10-12       Impact factor: 8.713

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.